Published in Blood on October 08, 2010
Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™ Transfus Med Hemother (2011) 1.04
Breathing easy with pathogen inactivation. Blood (2011) 0.81
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2015) 0.80
A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang (2015) 0.77
Stored platelet functionality is not decreased after warming with a fluid warmer. Anesth Analg (2013) 0.75
Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev (2017) 0.75
Cancer mortality in a Chinese population exposed to hexavalent chromium in drinking water. Epidemiology (2008) 3.39
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis (2012) 2.05
Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol (2002) 1.19
Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol (2004) 1.16
New frontiers in meningococcal vaccines. Expert Rev Vaccines (2011) 0.91
The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease. Hum Vaccin Immunother (2014) 0.91
Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion (2011) 0.86
Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion (2009) 0.82
Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease. Hum Vaccin Immunother (2012) 0.81
Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1. J Allergy Clin Immunol (2006) 0.76
Evaluation of platelet transfusion clinical trials. Br J Haematol (2011) 0.76
Titanium dioxide and lung cancer. J Occup Environ Med (2004) 0.75